Welcome to NGC. Skip directly to: Search Box, Navigation, Content.


Brief Summary

GUIDELINE TITLE

1) Immunizations. 2) Immunization update.

BIBLIOGRAPHIC SOURCE(S)

  • Institute for Clinical Systems Improvement (ICSI). Immunization update. Bloomington (MN): Institute for Clinical Systems Improvement (ICSI); 2007 Dec. 4 p.


  • Institute for Clinical Systems Improvement (ICSI). Immunizations. Bloomington (MN): Institute for Clinical Systems Improvement (ICSI); 2007 Oct. 67 p. [77 references]

GUIDELINE STATUS

This is the current release of the guideline.

This guideline updates a previous version:

  • Institute for Clinical Systems Improvement (ICSI). Immunizations update. Bloomington (MN): Institute for Clinical Systems Improvement (ICSI); 2006 Sep. 4 p. [69 references]
  • Institute for Clinical Systems Improvement (ICSI). Immunizations. Bloomington (MN): Institute for Clinical Systems Improvement (ICSI); 2006 Jun. 61 p. [69 references]
  • Institute for Clinical Systems Improvement (ICSI). Immunizations. Bloomington (MN): Institute for Clinical Systems Improvement (ICSI); 2007 Jan. 8 p.

** REGULATORY ALERT **

FDA WARNING/REGULATORY ALERT

Note from the National Guideline Clearinghouse: This guideline references a drug(s) for which important revised regulatory and/or warning information has been released.

BRIEF SUMMARY CONTENT

 ** REGULATORY ALERT **
 RECOMMENDATIONS
 EVIDENCE SUPPORTING THE RECOMMENDATIONS
 IDENTIFYING INFORMATION AND AVAILABILITY
 DISCLAIMER

 Go to the Complete Summary

RECOMMENDATIONS

MAJOR RECOMMENDATIONS

Notes from the National Guideline Clearinghouse (NGC) and the Institute for Clinical Systems Improvement (ICSI):

  • For a description of what has changed since the previous version of this guidance, refer to "Summary of Changes Report -- October 2007."
  • The recommendations for immunizations are presented in the form of immunization schedules and an algorithm with a total of 30 components accompanied by detailed annotations. Clinical highlights and immunization schedules are provided below for: Immunization Schedule for Infants, Children, and Adolescents – Routine and High Risk and Immunization Schedule for Adults -- Routine and High Risk. An algorithm for In-Clinic Immunization is provided in the original guideline document.
  • There have been, and will be again in the future, shortages and delays in the distribution of many of the recommended vaccines. The situation varies by location and health care provider. The work group recommends that all practitioners be kept abreast of the latest national information on vaccine shortage by accessing the Centers for Disease Control and Prevention (CDC)'s Web site at http://www.cdc.gov/vaccines/news/default.htm.
  • December 2007 Addendum: The Immunization Update is designed to provide current information and recommendations on Immunizations as released by the Centers for Disease Control that come in between the full revision of the guideline. The Immunization Update contains an immunization schedule as well as new or revised annotations to help the reader understand the options recommended for specific immunizations. This update provides revised recommendations for immunization against influenza for infants, children, and adolescents (routine and high-risk). Algorithm Annotation #9 in the original guideline document has been revised to reflect the new information, as well.

Clinical Highlights

  • Utilize all clinical encounters as opportunities to assess a patient's immunization status. (Annotation #17 - see the original guideline document)
  • Administer at each clinical encounter all immunizations that are due or overdue unless true contraindications exist. (Annotations #20, 21, 26 - see the original guideline document)
  • Educate patients and parents regarding the importance of infant, childhood, adolescent, and adult immunizations, the recommended schedule and the need to maintain a personal record of immunizations and childhood diseases. (Annotations #21, 23, 28 - see the original guideline document)
  • Document reasons for not administering immunizations that are clinically indicated, and flag the record for a recall appointment. (Annotations #28, 29 - see the original guideline document)
  • Document the future plan for administering immunizations. (Annotation #26, 28 - see the original guideline document)

*Immunization Schedule for Infants, Children, and Adolescents – Routine and High Risk

Vaccine Birth 1 mo 2 mos 4 mos 6 mos 12 mos 15 mos 18 mos 24 mos 4-6 yrs 11-12 yrs 15-18 yrs
DTaP     X X X X   X Tdap  
IPV     X X X   X    
MMR (MMRV) Combined measles, mumps, rubella and varicella vaccine (MMRV) is preferred for children 12 months through 12 years of age over separate injection of equivalent component vaccines. X     X    
Varicella X     X   X
verify second dose completed
Pneumococcal (PCV7)     X X X X          
Hib     X X X X          
Rotavirus     X X X            
Hep B
Schedule 1
X X   X        
Hep B
Schedule 2
  X X X        
Influenza       X (6 to 59 months, annually) X
annually
X
annually
Hep A         X X        
Meningococcal             X X
if previously not received
Human Papilloma Virus (HPV)         X
(3-dose series)
X
(Catch up if appropriate, 3-dose series)

Abbreviations: DTaP, diphtheria, tetanus, acellular pertussis; Hep A, hepatitis A; Hep B, hepatitis B; Hib, Haemophilus influenzae type b; IPV, inactivated poliovirus vaccine; MMR, measles, mumps, and rubella; Tdap, tetanus-diphtheria-acellular pertussis; TIV, trivalent influenza vaccine.

*Please check manufacturer specifications for dosing, as all time intervals may not be needed.

For additional information on immunizing high-risk patients, see Annotation #14 in the original guideline document.

*Immunization Schedule for Adults -- Routine and High-Risk

Vaccine 19-26 Years 27-39 Years 40-64 Years 65 Years and Older
Td/Tdap Tdap if previously not immunized, Td booster every 10 years Td booster
IPV Immunize if not previously immunized
MMR Persons born during or after 1957 should have 1-dose measles; a second dose may be required in special circumstances (see Annotation #3 in the original guideline document).  
Varicella X
verify second dose completed
For all adults who do not have evidence of immunity to varicella, give two doses of varicella vaccine with at least 28 days between the first and second doses. (See Annotation #4 in the original guideline document.)
Pneumococcal (PPV23) Immunize high risk groups once. Re-immunize those at risk of losing immunity once after 5 years. Immunize at 65 if not done previously. Re-immunize once if 1st received >5 years ago and before age 65 or an appropriate immunocompromising condition is present.
Hep B Universal immunization Immunize those at high risk.
Influenza Annually during flu season for individuals age 50 and older, those at high risk, and others.
Hep A Immunize those in risk groups
Meningococcal X Immunize those in risk groups
Human Papilloma Virus (HPV) X
Catch up, if appropriate,
     
Herpes Zoster/Shingles     Immunize at age 60 and older

Abbreviations: Hep A, hepatitis A; Hep B, hepatitis B; IPV, inactivated polio vaccine; MMR, measles, mumps, rubella; Td, tetanus, diphtheria; Tdap, tetanus-diphtheria-acellular pertussis

*Please check manufacturer specifications for dosing, as all time intervals may not be needed.

For additional information on immunizing high-risk patients, see Annotation #14 in the original guideline document.

The Centers for Disease Control and Prevention (CDC) updates immunizations recommendations in January, July, and October -- please refer to the CDC website http://www.cdc.gov/vaccines/default.htm for the most current schedule.

CLINICAL ALGORITHM(S)

A detailed and annotated clinical algorithm titled "In-Clinic Immunization Algorithm" is provided in the original guideline document.

EVIDENCE SUPPORTING THE RECOMMENDATIONS

TYPE OF EVIDENCE SUPPORTING THE RECOMMENDATIONS

The type of supporting evidence is not stated for each recommendation.

IDENTIFYING INFORMATION AND AVAILABILITY

BIBLIOGRAPHIC SOURCE(S)

  • Institute for Clinical Systems Improvement (ICSI). Immunization update. Bloomington (MN): Institute for Clinical Systems Improvement (ICSI); 2007 Dec. 4 p.


  • Institute for Clinical Systems Improvement (ICSI). Immunizations. Bloomington (MN): Institute for Clinical Systems Improvement (ICSI); 2007 Oct. 67 p. [77 references]

ADAPTATION

Not applicable: The guideline was not adapted from another source.

DATE RELEASED

2007 Oct (addendum released 2007 Dec)

GUIDELINE DEVELOPER(S)

Institute for Clinical Systems Improvement - Private Nonprofit Organization

GUIDELINE DEVELOPER COMMENT

Organizations participating in the Institute for Clinical Systems Improvement (ICSI): Affiliated Community Medical Centers, Allina Medical Clinic, Altru Health System, Aspen Medical Group, Avera Health, CentraCare, Columbia Park Medical Group, Community-University Health Care Center, Dakota Clinic, ENT Specialty Care, Fairview Health Services, Family HealthServices Minnesota, Family Practice Medical Center, Gateway Family Health Clinic, Gillette Children's Specialty Healthcare, Grand Itasca Clinic and Hospital, HealthEast Care System, HealthPartners Central Minnesota Clinics, HealthPartners Medical Group and Clinics, Hutchinson Area Health Care, Hutchinson Medical Center, Lakeview Clinic, Mayo Clinic, Mercy Hospital and Health Care Center, MeritCare, Mille Lacs Health System, Minnesota Gastroenterology, Montevideo Clinic, North Clinic, North Memorial Care System, North Suburban Family Physicians, Northwest Family Physicians, Olmsted Medical Center, Park Nicollet Health Services, Pilot City Health Center, Quello Clinic, Ridgeview Medical Center, River Falls Medical Clinic, Saint Mary's/Duluth Clinic Health System, St. Paul Heart Clinic, Sioux Valley Hospitals and Health System, Southside Community Health Services, Stillwater Medical Group, SuperiorHealth Medical Group, University of Minnesota Physicians, Winona Clinic, Ltd., Winona Health

ICSI, 8009 34th Avenue South, Suite 1200, Bloomington, MN 55425; telephone, (952) 814-7060; fax, (952) 858-9675; e-mail: icsi.info@icsi.org; Web site: www.icsi.org.

SOURCE(S) OF FUNDING

The following Minnesota health plans provide direct financial support: Blue Cross and Blue Shield of Minnesota, HealthPartners, Medica, Metropolitan Health Plan, PreferredOne and UCare Minnesota. In-kind support is provided by the Institute for Clinical Systems Improvement's (ICSI) members.

GUIDELINE COMMITTEE

Preventive Services Steering Committee

COMPOSITION OF GROUP THAT AUTHORED THE GUIDELINE

Work Group Members: James Nordin, MD (Work Group Leader) (HealthPartners Medical Group) (Pediatrics); Emma Carlin, MD (Park Nicollet Health Services) (Family Medicine); Barbara Yawn, MD (Olmsted Medical Center) (Family Medicine); Lawrence Kerzner, MD (Hennepin County Medical Center) (Geriatrics); Lisa Moorhoorse, RN (Fairview Health Services) (Nursing); Barb Ottis, RN (Park Nicollet Health Services) (Nursing); Renner Anderson, MD (Park Nicollet Health Services) (Pediatrics); Robert Jacobson, MD (Mayo Clinic) (Pediatrics); Penny Fredrickson (Institute for Clinical Systems Improvement) (Implementation Advisor); Melissa Marshall, MBA (Institute for Clinical Systems Improvement) (Facilitator)

FINANCIAL DISCLOSURES/CONFLICTS OF INTEREST

GUIDELINE STATUS

This is the current release of the guideline.

This guideline updates a previous version:

  • Institute for Clinical Systems Improvement (ICSI). Immunizations update. Bloomington (MN): Institute for Clinical Systems Improvement (ICSI); 2006 Sep. 4 p. [69 references]
  • Institute for Clinical Systems Improvement (ICSI). Immunizations. Bloomington (MN): Institute for Clinical Systems Improvement (ICSI); 2006 Jun. 61 p. [69 references]
  • Institute for Clinical Systems Improvement (ICSI). Immunizations. Bloomington (MN): Institute for Clinical Systems Improvement (ICSI); 2007 Jan. 8 p.

GUIDELINE AVAILABILITY

Electronic copies of the original guideline and the addendum: Available from the Institute for Clinical Systems Improvement (ICSI) Web site.

Print copies: Available from ICSI, 8009 34th Avenue South, Suite 1200, Bloomington, MN 55425; telephone, (952) 814-7060; fax, (952) 858-9675; Web site: www.icsi.org; e-mail: icsi.info@icsi.org.

AVAILABILITY OF COMPANION DOCUMENTS

The following are available:

Print copies: Available from ICSI, 8009 34th Avenue South, Suite 1200, Bloomington, MN 55425; telephone, (952) 814-7060; fax, (952) 858-9675; Web site: www.icsi.org; e-mail: icsi.info@icsi.org.

PATIENT RESOURCES

None available

NGC STATUS

This summary was completed by ECRI on August 30, 1999. The information was verified by the guideline developer on October 11, 1999. This summary was updated by ECRI on May 15, 2000 and on October 22, 2001. This summary was updated by ECRI on December 4, 2002. The updated information was verified by the guideline developer on December 24, 2002. This summary was updated by ECRI on April 12, 2004, September 20, 2004, August 9, 2005, July 5, 2006, November, 30, 2006, and March 6, 2007. This summary was updated by ECRI Institute on July 9, 2007 following the FDA advisory on RotaTeq (Rotavirus, Live, Oral, Pentavalent) vaccine. This NGC summary was updated by ECRI Institute on December 18, 2007.

COPYRIGHT STATEMENT

This NGC summary (abstracted ICSI Guideline) is based on the original guideline, which is subject to the guideline developer's copyright restrictions.

The abstracted ICSI Guidelines contained in this Web site may be downloaded by any individual or organization. If the abstracted ICSI Guidelines are downloaded by an individual, the individual may not distribute copies to third parties.

If the abstracted ICSI Guidelines are downloaded by an organization, copies may be distributed to the organization's employees but may not be distributed outside of the organization without the prior written consent of the Institute for Clinical Systems Improvement, Inc.

All other copyright rights in the abstracted ICSI Guidelines are reserved by the Institute for Clinical Systems Improvement, Inc. The Institute for Clinical Systems Improvement, Inc. assumes no liability for any adaptations or revisions or modifications made to the abstracts of the ICSI Guidelines.

DISCLAIMER

NGC DISCLAIMER

The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.

All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.

Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at http://www.guideline.gov/about/inclusion.aspx .

NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding guideline content are directed to contact the guideline developer.


 

 

   
DHHS Logo